AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
Phase 3negativevolrustomigNegative
AI Analysis
Summary
AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy for first-line metastatic NSCLC in August, representing a significant setback in the competitive PD-1 bispecific market.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
eVOLVE-Lung02 Phase III trial discontinued in August
Importance:8/10
Sentiment:
-0.85
Phase 3 failurePD-1 bispecificNSCLCtrial discontinuationoncology
Related Companies
Read the original article
Published by Clinical Trials Arena on August 21, 2026 9:32 AM